文献速递乳腺癌

替吉奥与卡培他滨治疗进展期乳腺癌的多中心临床研究比较

[A multicenter clinical study for the comparison of S-1 versus capecitabine in the treatment of advanced breast cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2017-01-01

该多中心研究纳入2012年1月1日至2014年12月31日病理确诊的154例进展期乳腺癌患者,比较替吉奥组(70例)与卡培他滨组(84例)的疗效、安全性及预后因素。两组客观反应率和疾病控制率差异均无统计学意义,替吉奥组血红蛋白降低发生率低于卡培他滨组。

要点

  • 替吉奥组与卡培他滨组客观反应率分别为31.4%和28.6%,疾病控制率分别为74.3%和83.3%,差异均无统计学意义。
  • 单药卡培他滨组疾病控制率94.4%高于单药替吉奥组64.0%(P=0.028)。
  • 替吉奥组血红蛋白降低发生率14.3%低于卡培他滨组36.9%(P=0.002)。

核心结论

  • 替吉奥和卡培他滨均为治疗进展期乳腺癌的有效药物,两组客观反应率和疾病控制率差异均无统计学意义。
  • 替吉奥的消化道反应和血小板减少发生率略低于卡培他滨。

研究设计与样本

  • 多中心临床研究,纳入2012年1月1日至2014年12月31日病理确诊的154例进展期乳腺癌患者。
  • 患者分为替吉奥组(70例,单药替吉奥或联合三代化疗药)和卡培他滨组(84例,单药卡培他滨或联合三代化疗药),比较疗效、不良反应及预后因素。

主要发现

  • 替吉奥组与卡培他滨组客观反应率分别为31.4%(22/70)和28.6%(24/84),疾病控制率分别为74.3%(52/70)和83.3%(70/84),差异均无统计学意义(均P>0.05)。
  • 单药卡培他滨组疾病控制率94.4%(17/18)高于单药替吉奥组64.0%(16/25),差异有统计学意义(P=0.028)。
  • 替吉奥组与卡培他滨组中位无进展生存时间分别为7.5个月和8.9个月,差异无统计学意义(P=0.423)。
  • 替吉奥组与卡培他滨组1年生存率分别为81.4%和66.7%,差异有统计学意义(P=0.020)。
  • 单因素分析显示ER和(或)PR状态(P=0.004)、T分期(P=0.041)、分子分型(P=0.046)与无进展生存时间有关;多因素分析显示ER和(或)PR状态为独立预后因素(P=0.034)。

关键数值与推荐

  • 替吉奥组与卡培他滨组血红蛋白降低发生率分别为14.3%(10/70)和36.9%(31/84),差异有统计学意义(P=0.002)。
  • 两组白细胞减少、中性粒细胞减少、血小板减少、手足综合征发生率差异均无统计学意义(均P>0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the safety, efficacy and prognostic factors of S-1 versus capecitabine in patients with advanced breast cancer (ABC). Methods: From January 1, 2012 to December 31, 2014, 154 ABC patients with pathological diagnosis were separated into two groups: S-1 with or without the 3rd generation chemotherapy drug (group S-1) and capecitabine with or without the 3rd generation chemotherapy drug (Group capecitabine). The efficacy, side effects and prognostic factors were compared between the two groups. Results: There were 70 patients in group S-1 and 84 patients in group capecitabine. The objective response rates (ORR) were 31.4% (22/70) in group S-1 and 28.6% (24/84) in group capecitabine. The disease control rates (DCR) were 74.3% (52/70) and 83.3% (70/84), respectively. There were no significant differences in DCR and ORR between two groups (P>0.05). The DCR of patients treated with capecitabine monotherapy was significantly higher than that of S-1 monotherapy [94.4%(17/18) and 64.0%(16/25), P=0.028]. The median PFS was 7.5 and 8.9 months for the patients in the group S-1 and group capecitabine, with no statistically significant difference (P=0.423). The 1-year survival rates of group S-1 and group capecitabine were 81.4% and 66.7%, respectively, with no significant differences(P=0.020). Univariate analysis showed that ER and/or PR status (P=0.004), T stage (P=0.041), and molecular typing (P=0.046) were associated with PFS. Multivariate analysis showed ER and/or PR status (P=0.034) was an independent prognostic factor related with PFS. The incidence of hemoglobin reduction was 14.3% (10/70) and 36.9% (31/84) in the group S-1 and group capecitabine, and the differences were statistically significant (P=0.002). There was no significant difference in the incidence of leukopenia, neutropenia, thrombocytopenia and hand-foot syndrome between the two groups(P>0.05). Conclusions: S-1 and capecitabine are both effective for advanced breast cancer. Neither ORR nor DCR were significantly different between these two groups. The incidence of gastrointestinal reactions and thrombocytopenia of S-1 was slightly lower than that of capecitabine. 目的: 分析替吉奥和卡培他滨治疗进展期乳腺癌(ABC)的疗效、安全性及预后相关因素。 方法: 收集2012年1月1日至2014年12月31日间病理确诊的154例ABC患者,将患者分为替吉奥组和卡培他滨组。其中替吉奥组给予单药替吉奥或者联合三代化疗药,卡培他滨组给予单药卡培他滨或者联合三代化疗药,观察患者的治疗效果、不良反应发生情况及其预后相关因素。 结果: 154例ABC患者中,替吉奥组70例,卡培他滨组84例。替吉奥组和卡培他滨组患者的客观反应率(ORR)分别为31.4%(22/70)和28.6%(24/84),疾病控制率(DCR)分别为74.3%(52/70)和83.3%(70/84),差异均无统计学意义(均P>0.05)。单药卡培他滨和单药替吉奥治疗患者的DCR分别为94.4%(17/18)和64.0%(16/25),差异有统计学意义(P=0.028)。替吉奥组和卡培他滨组患者的中位无进展生存时间(PFS)分别为7.5和8.9个月,差异无统计学意义(P=0.423)。替吉奥组和卡培他滨组患者的1年生存率分别为81.4%和66.7%,差异有统计学意义(P=0.020)。单因素分析显示,ER和(或)PR状态(P=0.004)、T分期(P=0.041)、分子分型(P=0.046)与ABC患者PFS有关。多因素分析显示,ER和(或)PR状态为影响ABC患者PFS的独立因素(P=0.034)。替吉奥组和卡培他滨组患者的血红蛋白降低发生率分别为14.3% (10/70)和36.9% (31/84),差异有统计学意义(P=0.002)。两组患者白细胞减少、中性粒细胞减少、血小板减少、手足综合征的发生率差异均无统计学意义(均P>0.05)。 结论: 替吉奥和卡培他滨均为治疗ABC的有效药物,其ORR和DCR差异均无统计学意义,但替吉奥的消化道反应和血小板减少的发生率略低于卡培他滨。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li Y, Jiang D, Wu YY, et al. [A multicenter clinical study for the comparison of S-1 versus capecitabine in the treatment of advanced breast cancer]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28835084. doi:10.3760/cma.j.issn.0253-3766.2017.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。